Design, synthesis, and biological evaluation of histone deacetylase inhibitor with novel salicylamide zinc binding group.

ABSTRACT:

Introduction

Histone deacetylases (HDACs) have emerged as important therapeutic targets for various diseases, such as cancer and neurological disorders. Although a majority of HDAC inhibitors use hydroxamic acids as zinc binding groups, hydroxamic acid zinc-binding groups suffer from poor bioavailability and nonspecific metal-binding properties, necessitating a new zinc-binding group. Salicylic acid and its derivatives, well-known for their therapeutic value, have also been reported to chelate zinc ions in a bidentate fashion. This drew our attention towards replacing hydroxamic acid with salicylamide as a zinc-binding group.

Methods

In this study, for the first time, compound 5 possessing a novel salicylamide zinc-binding group was synthesized and evaluated biologically for

SUBMITTER: Kim JH 

PROVIDER: S-EPMC9276175 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature